The LD78 beta isoform of MIP-1 alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine

Citation
P. Menten et al., The LD78 beta isoform of MIP-1 alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine, J CLIN INV, 104(4), 1999, pp. R1-R5
Citations number
27
Categorie Soggetti
Medical Research General Topics
Journal title
JOURNAL OF CLINICAL INVESTIGATION
ISSN journal
00219738 → ACNP
Volume
104
Issue
4
Year of publication
1999
Pages
R1 - R5
Database
ISI
SICI code
0021-9738(199908)104:4<R1:TLBIOM>2.0.ZU;2-5
Abstract
LD78 alpha and LD78 beta are 2 highly related nonallelic genes that code fo r different isoforms of the human CC chemokine macrophage inflammatory prot ein-1 alpha (MIP-1 alpha). Two molecular forms of natural LD78 beta (7.778 and 7.793 kDa) were identified from conditioned media of stimulated periphe ral blood mononuclear cells. Although LD78 alpha and LD78 beta only differ in 3 amino acids, both LD78 beta variants were 100-fold more potent chemoat tractants for mouse lymphocytes than was LD78 alpha. On the contrary, LD78 beta was only 2-fold more efficient than LD78 alpha in chemoattracting huma n lymphocytes and monocytes. Using CC chemokine receptor-transfected cells, both molecular forms of LD78 beta proved to be much more potent than LD78 alpha in inducing an intracellular calcium rise through CCR5. Compared with LD78 alpha and RANTES, this preferential binding of LD78 beta to CCR5 resu lted in a 10- to 50-fold higher potency in inhibiting infection of peripher al blood mononuclear cells by CCR5-using (R5) HIV-1 strains. To date, LD78 beta is the most potent chemokine for inhibiting HIV-1 infection, and can b e considered as a potentially important drug candidate for the treatment of infection with R5 HIV-1 strains.